🌍·1d agodiscovery
Samsung Bioepis First to Prove Equivalence in Phase 3 Trial for Keytruda Biosimilar, Targeting $29.8 Billion Market
Publisher
B
BigGo Finance
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- BigGo Finance
- Region
- Global
- Scope
- discovery
- Published
- June 29, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: BigGo Finance
Scope: discovery
Related coverage
More related coverage
openFDA Drug Labels/-407m ago
Drug label update: Evereden Kids Mineral Sunscreen SPF 30
Official structured record identifier: bba219a4-de83-76fd-e053-2995a90a2d69.
openFDA Drug Labels/-407m ago
Drug label update: GUNA-VIRUS
Official structured record identifier: 53e741c4-8897-71f3-e063-6394a90a751d.
geneonline.com/1h ago
FDA Selects Seven Pharmaceutical Companies for PreCheck Supply Chain Pilot Program
Pharmaceutical Technology/1h ago